Cargando…
Characterizing the Bone Marrow Environment in Advanced-Stage Myelofibrosis during Ruxolitinib Treatment Using PET/CT and MRI: A Pilot Study
Current diagnostic criteria for myelofibrosis are largely based on bone marrow (BM) biopsy results. However, these have several limitations, including sampling errors. Explorative studies have indicated that imaging might form an alternative for the evaluation of disease activity, but the heterogene...
Autores principales: | Slot, Stefanie, Lavini, Cristina, Zwezerijnen, Gerben J. C., Boden, Bouke J. H., Marcus, J. Tim, Huisman, Marc C., Yaqub, Maqsood, Barbé, Ellis, Wondergem, Mariëlle J., Zijlstra, Josée M., Zweegman, Sonja, Raijmakers, Pieter G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037592/ https://www.ncbi.nlm.nih.gov/pubmed/36960997 http://dx.doi.org/10.3390/tomography9020038 |
Ejemplares similares
-
The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review
por: Slot, Stefanie, et al.
Publicado: (2021) -
Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013) -
Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016) -
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023) -
Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)